#ICYMI: Watch this video to learn how we’re tackling one of the biggest challenges in immunotherapy. At Aulos, we believe our lead asset, AU-007, could be the answer to safely harness IL-2 and fight cancer effectively. See how we’re unlocking the power of IL-2. #Innovation #Oncology #IL2
Aulos Bioscience
Biotechnology Research
Larkspur, California 1,962 followers
We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immunesystem to destroy cancers.
About us
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Website
-
https://aulosbio.com/
External link for Aulos Bioscience
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Larkspur, California
- Type
- Privately Held
- Specialties
- immuno oncology , oncology, monoclonal antibodies, and cancer research
Locations
-
Primary
Get directions
700 Larkspur Landing Circle
Suite 108
Larkspur, California 94939, US
Employees at Aulos Bioscience
Updates
-
We’re presenting at the American Association for Cancer Research Annual Meeting! Come by and see our Phase 2 data that focuses on promising results for our lead candidate in second-line treatment of melanoma. We hope to meet you in person this April. Read the full release: https://bit.ly/4hEZcLH #AACR25 #Oncology #Melanoma
-
-
Our Phase 1/2 clinical trial of AU-007, a novel IL-2 therapeutic for the treatment of solid tumors, is enrolling patients in the U.S. To learn more about this study and how patients may qualify, visit: https://lnkd.in/eB4Qd82U #Oncology #ClinicalTrial #SolidTumor
-
Our novel therapeutic antibody was designed based on our belief that a biologic agent that looks like a natural antibody may be the key to unlocking the power of IL-2. See how our approach is different: https://bit.ly/3EuM3XZ #IL2 #Oncology Bioprocess Online
-
Our lead asset, AU-007, is a human monoclonal antibody that we believe could safely and effectively unlock the anti-cancer power of interleukin-2 to fundamentally change cancer treatment. See how we’ve designed a drug candidate that could solve one of the biggest challenges in immunotherapy. Learn more: https://bit.ly/4b5W1v7 #Innovation #Oncology #IL2
-
Based on a growing body of evidence, our lead asset continues to demonstrate a well-tolerated safety profile and durable anti-tumor activity. Learn why our approach in redirecting IL-2 is showing promise: https://bit.ly/3EuM3XZ #Oncology #IL2 #Cancer
-
-
At Aulos, we’re working to bring markedly improved treatment options to patients diagnosed with solid tumor cancers. Read about our mission and the values that guide us: https://bit.ly/40FqrR0 #Mission #Values #Oncology #Biopharma
-
-
Good luck to all those presenting and networking at #JPM2025. We hope you enjoy your time in our hometown. If you’re attending the J.P. Morgan Healthcare Conference, we thought you might enjoy some history about the The Westin St. Francis San Francisco on Union Square. #JPM25 #JPMHC25 #biotech
-
We were thrilled at the progress made in 2024 and we are excited for what the #NewYear will bring. Thank you to everyone who met us in person, participated in our trial or encouraged us online. Have a happy holiday season! #HappyHolidays #BioTech #HappyNewYear
-
Following the science is a key discipline for success. Listen to our CEO, Aron Knickerbocker, and his advice for the next generation in #biotech, including how this principle has guided him throughout his career: https://bit.ly/3YIbVpB #Oncology #BusinessofBiotech Bioprocess Online